OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced interim results from the VISIBLE open-label extension (OLE) study on the long-term ...

Furthermore, treatment with vedolizumab was associated with significantly higher rates of mucosal healing** at week 52, with 39.7% of patients receiving vedolizumab achieving mucosal healing compared ...

Vedolizumab is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either ...

In May, the U.S. Food and Drug Administration (FDA) simultaneously approved Entyvio for the treatment of adults with moderately to severely active UC and CD. That same month, Entyvio was also granted ...

Among more than 1,300 patients who received vedolizumab, 88.8% of those who received the drug within 30 days after being diagnosed responded to treatment versus 70.1% to 79.8% when the treatment was ...

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...

The US Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of vedolizumab (Entyvio SC, Takeda) for maintenance therapy in adults with moderately to severely active ...

The US Food and Drug Administration (FDA) today approved vedolizumab (Entyvio, Takeda Pharmaceuticals USA, Inc) injection for treatment of adults with moderate to severe ulcerative colitis and adults ...

− Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease − ...

Furthermore, treatment with vedolizumab was associated with significantly higher rates of mucosal healing** at week 52, with 39.7% of patients receiving vedolizumab achieving mucosal healing compared ...